This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.

The overall study duration will be approximately 16 weeks. After a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 0.3mg tablets

Inclusion Criteria:

• Naturally or surgically postmenopausal
• At least 12 months since last menses or 6 weeks past surgery
• Minimum of 7 daily or 50 weekly moderate to severe hot flashes

Exclusion Criteria:

• Any contraindication to natural or synthetic estrogens